Clinical Trials: SEARCH[Study] TILT[Study:StudyFirstPostDate] AREA[ConditionSearch] Anemia
First Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 … 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 Next Last
#
NCTID/Status
Study
Last Changed
2701
NCT03432364
Recruiting
Recruiting
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Conditions: Transfusion Dependent Beta-thalassemia
Intervention: ST-400 Investigational Product
Conditions: Transfusion Dependent Beta-thalassemia
Intervention: ST-400 Investigational Product
September 12, 2019
2702
NCT03891277
Not yet recruiting
Not yet recruiting
Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA (FAVORITE)
Conditions: Vascular Cognitive Impairment; Dementia, Vascular; Iron-deficiency; Cerebral Infarction; TIA
Intervention: Ferrous Succinate
Conditions: Vascular Cognitive Impairment; Dementia, Vascular; Iron-deficiency; Cerebral Infarction; TIA
Intervention: Ferrous Succinate
March 23, 2019
2703
NCT01363908
Terminated
Terminated
Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
Conditions: Transfusional Iron Overload; Beta-Thalassemia
Intervention: SPD602
Conditions: Transfusional Iron Overload; Beta-Thalassemia
Intervention: SPD602
May 27, 2015
2704
NCT01186419
Completed
Completed
Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
Conditions: Transfusional Iron Overload; Beta-thalassemia
Intervention: SPD602 (FBS0701, SSP-004184)
Conditions: Transfusional Iron Overload; Beta-thalassemia
Intervention: SPD602 (FBS0701, SSP-004184)
June 3, 2015
2705
NCT01039636
Completed
Completed
Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload
Conditions: Transfusional Iron Overload; Beta-thalassemia
Intervention: FBS0701
Conditions: Transfusional Iron Overload; Beta-thalassemia
Intervention: FBS0701
February 8, 2012
2706
NCT03720184
Recruiting
Recruiting
Haemo-autologous Antegrade Repriming (HAR) as Minimum Impact Perfusion Strategy for Cardiopulmonary Bypass
Conditions: Anemia; Cognitive; Disorder, Due to General Medical Condition; Embolism, Air; Transfusion; Cardiac Disease; Extracorporeal Circulation; Complications; Valve Anomalies
Intervention: HAR, Self-venting Technology
Conditions: Anemia; Cognitive; Disorder, Due to General Medical Condition; Embolism, Air; Transfusion; Cardiac Disease; Extracorporeal Circulation; Complications; Valve Anomalies
Intervention: HAR, Self-venting Technology
October 31, 2018
2707
NCT03886753
Recruiting
Recruiting
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products
Conditions: ALS; Autism Spectrum Disorder; Cancer; Spasticity, Muscle; Dyskinetic Syndrome; Epilepsy; Glaucoma; Huntington Disease; Inflammatory Bowel Disease (IBD); Multiple Sclerosis; Neuropathy; Opioid Use; Parkinson Disease; HIV/AIDS; Ptsd; Intractable Pain; Sickle Cell Disease; Terminal Illness
Intervention: Registry, PK Microsampling Of Blood
Conditions: ALS; Autism Spectrum Disorder; Cancer; Spasticity, Muscle; Dyskinetic Syndrome; Epilepsy; Glaucoma; Huntington Disease; Inflammatory Bowel Disease (IBD); Multiple Sclerosis; Neuropathy; Opioid Use; Parkinson Disease; HIV/AIDS; Ptsd; Intractable Pain; Sickle Cell Disease; Terminal Illness
Intervention: Registry, PK Microsampling Of Blood
June 11, 2019
2708
NCT03944447
Recruiting
Recruiting
Outcomes Mandate National Integration With Cannabis as Medicine
Conditions: Chronic Pain; Chronic Pain Syndrome; Chronic Pain Due to Injury; Chronic Pain Due to Trauma; Fibromyalgia; Seizures; Hepatitis C; Cancer; Crohn Disease; HIV/AIDS; Multiple Sclerosis; Traumatic Brain Injury; Sickle Cell Disease; Post Traumatic Stress Disorder; Tourette Syndrome; Ulcerative Colitis; Glaucoma; Epilepsy; Inflammatory Bowel Diseases; Parkinson Disease; Amyotrophic Lateral Sclerosis; Chronic Traumatic Encephalopathy; Anxiety; Depression; Insomnia; Autism; Opioid-use Disorder; Bipolar Disorder
Intervention: Cannabis, Medical
Conditions: Chronic Pain; Chronic Pain Syndrome; Chronic Pain Due to Injury; Chronic Pain Due to Trauma; Fibromyalgia; Seizures; Hepatitis C; Cancer; Crohn Disease; HIV/AIDS; Multiple Sclerosis; Traumatic Brain Injury; Sickle Cell Disease; Post Traumatic Stress Disorder; Tourette Syndrome; Ulcerative Colitis; Glaucoma; Epilepsy; Inflammatory Bowel Diseases; Parkinson Disease; Amyotrophic Lateral Sclerosis; Chronic Traumatic Encephalopathy; Anxiety; Depression; Insomnia; Autism; Opioid-use Disorder; Bipolar Disorder
Intervention: Cannabis, Medical
September 22, 2019
2709
NCT03303950
Recruiting
Recruiting
Busulfan, Fludarabine, Donor Stem Cell Transplant, and Cyclophosphamide in Treating Patients With Multiple Myeloma or Myelofibrosis
Conditions: Anemia; ASXL1 Gene Mutation; EZH2 Gene Mutation; IDH1 Gene Mutation; IDH2 Gene Mutation; Plasma Cell Myeloma; Primary Myelofibrosis; Recurrent Plasma Cell Myeloma; Secondary Myelofibrosis; Thrombocytopenia
Intervention: Busulfan, Cyclophosphamide, Fludarabine, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis
Conditions: Anemia; ASXL1 Gene Mutation; EZH2 Gene Mutation; IDH1 Gene Mutation; IDH2 Gene Mutation; Plasma Cell Myeloma; Primary Myelofibrosis; Recurrent Plasma Cell Myeloma; Secondary Myelofibrosis; Thrombocytopenia
Intervention: Busulfan, Cyclophosphamide, Fludarabine, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis
May 10, 2019
2710
NCT03010358
Recruiting
Recruiting
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Conditions: Anemia; B-Cell Prolymphocytic Leukemia; Fatigue; Fever; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Hairy Cell Leukemia; Lymphadenopathy; Lymphocytosis; Lymphoplasmacytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Night Sweats; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma; Richter Syndrome; Splenomegaly; Thrombocytopenia; Weight Loss
Intervention: Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab, Pharmacological Study
Conditions: Anemia; B-Cell Prolymphocytic Leukemia; Fatigue; Fever; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Hairy Cell Leukemia; Lymphadenopathy; Lymphocytosis; Lymphoplasmacytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Night Sweats; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma; Richter Syndrome; Splenomegaly; Thrombocytopenia; Weight Loss
Intervention: Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab, Pharmacological Study
September 28, 2018
2711
NCT02948283
Active, not recruiting
Active, not recruiting
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
Conditions: Anemia; Fatigue; Fever; Lymphadenopathy; Lymphocytosis; Night Sweats; Recurrent Chronic Lymphocytic Leukemia; Recurrent Plasma Cell Myeloma; Refractory Chronic Lymphocytic Leukemia; Refractory Plasma Cell Myeloma; Splenomegaly; Thrombocytopenia; Weight Loss
Intervention: Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study, Ritonavir, Quality-of-Life, Questionnaire
Conditions: Anemia; Fatigue; Fever; Lymphadenopathy; Lymphocytosis; Night Sweats; Recurrent Chronic Lymphocytic Leukemia; Recurrent Plasma Cell Myeloma; Refractory Chronic Lymphocytic Leukemia; Refractory Plasma Cell Myeloma; Splenomegaly; Thrombocytopenia; Weight Loss
Intervention: Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study, Ritonavir, Quality-of-Life, Questionnaire
September 24, 2019
2712
NCT02530515
Completed
Completed
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
Conditions: Anemia; Cancer Fatigue; Chronic Lymphocytic Leukemia; Fever; Infectious Disorder; Lymphadenopathy; Lymphocytosis; Night Sweats; Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Richter Syndrome; Secondary Malignant Neoplasm; Thrombocytopenia; Weight Loss
Intervention: Ex Vivo-activated Autologous Lymph Node Lymphocytes, Laboratory Biomarker Analysis
Conditions: Anemia; Cancer Fatigue; Chronic Lymphocytic Leukemia; Fever; Infectious Disorder; Lymphadenopathy; Lymphocytosis; Night Sweats; Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Richter Syndrome; Secondary Malignant Neoplasm; Thrombocytopenia; Weight Loss
Intervention: Ex Vivo-activated Autologous Lymph Node Lymphocytes, Laboratory Biomarker Analysis
December 6, 2018
2713
NCT03344887
Recruiting
Recruiting
An Innovative Trial Assessing Donor Sex on Recipient Mortality
Conditions: Red Blood Cell Transfusion
Intervention: RBC Transfusion From Male Donor, RBC Transfusion From Female Donor
Conditions: Red Blood Cell Transfusion
Intervention: RBC Transfusion From Male Donor, RBC Transfusion From Female Donor
September 5, 2018
2714
NCT02596087
Unknown status
Unknown status
Improving Quality by Maintaining Accurate Problems in the EHR
Conditions: Asthma; Atrial Fibrillation; Chronic Obstructive Pulmonary Disease; Coronary Artery Disease; Congestive Heart Failure; Hyperlipidemia; Hypertension; Myocardial Infarction; Sickle Cell Disease; Sleep Apnea; Smoking; Stroke; Tuberculosis
Intervention: Problem List Suggestion
Conditions: Asthma; Atrial Fibrillation; Chronic Obstructive Pulmonary Disease; Coronary Artery Disease; Congestive Heart Failure; Hyperlipidemia; Hypertension; Myocardial Infarction; Sickle Cell Disease; Sleep Apnea; Smoking; Stroke; Tuberculosis
Intervention: Problem List Suggestion
December 5, 2016
2715
NCT03945968
Recruiting
Recruiting
The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.
Conditions: Coronary Heart Disease; Anemia; Bronchial Asthma; Stroke; Epilepsy; Parkinson's Disease; Heart Rhythm Disorders; Alzheimer's Disease; Neuromuscular Diseases; Diabetes; Chronic Heart Failure; Chronic Obstructive Pulmonary Disease; Chronic Kidney Diseases
Conditions: Coronary Heart Disease; Anemia; Bronchial Asthma; Stroke; Epilepsy; Parkinson's Disease; Heart Rhythm Disorders; Alzheimer's Disease; Neuromuscular Diseases; Diabetes; Chronic Heart Failure; Chronic Obstructive Pulmonary Disease; Chronic Kidney Diseases
October 7, 2019
2716
NCT02118402
Completed
Completed
Iron and Prebiotics Fortification in Kenyan Infants
Conditions: Anemia; Iron Deficiency; Diarrhea; Malaria; Respiratory Tract Infections (RTI); Antibiotics; Gut Inflammation; Prebiotics
Intervention: Fortified Maize Porridge
Conditions: Anemia; Iron Deficiency; Diarrhea; Malaria; Respiratory Tract Infections (RTI); Antibiotics; Gut Inflammation; Prebiotics
Intervention: Fortified Maize Porridge
April 8, 2017
2717
NCT01196533
Completed
Completed
A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters
Conditions: Anemia; Diabetes; Heart Disease; High Blood Pressure; Hypotension; Metabolic Diseases; Respiratory Diseases
Intervention: Non Invasive Peripheral Blood Monitoring
Conditions: Anemia; Diabetes; Heart Disease; High Blood Pressure; Hypotension; Metabolic Diseases; Respiratory Diseases
Intervention: Non Invasive Peripheral Blood Monitoring
January 30, 2019
2718
NCT01105923
Unknown status
Unknown status
Study of an Intervention to Improve Problem List Accuracy and Use
Conditions: Attention Deficit Disorder With Hyperactivity; Asthma; COPD; Breast Cancer; Coronary Artery Disease; Congestive Heart Failure; Diabetes; Glaucoma; Hemophilia; Hypertension; Hyperthyroidism; Hypothyroidism; Myasthenia Gravis; Osteoporosis; Osteopenia; Renal Failure; Renal Insufficiency; Sickle Cell Disease; Stroke
Intervention: MAPLE
Conditions: Attention Deficit Disorder With Hyperactivity; Asthma; COPD; Breast Cancer; Coronary Artery Disease; Congestive Heart Failure; Diabetes; Glaucoma; Hemophilia; Hypertension; Hyperthyroidism; Hypothyroidism; Myasthenia Gravis; Osteoporosis; Osteopenia; Renal Failure; Renal Insufficiency; Sickle Cell Disease; Stroke
Intervention: MAPLE
January 30, 2015
2719
NCT02567981
Recruiting
Recruiting
Comparison of Two Nutrition Interventions in Young Children in El Salvador
Conditions: Micronutrient Deficiency
Intervention: 21 Micronutrient-fortified Supplement, Cereal Fortificado (Fortified Cereal), Ferrous Sulphate, Vitamin A
Conditions: Micronutrient Deficiency
Intervention: 21 Micronutrient-fortified Supplement, Cereal Fortificado (Fortified Cereal), Ferrous Sulphate, Vitamin A
November 3, 2016
2720
NCT02797353
Completed
Completed
Strengthening Maternal Neonatal and Child Health Services in a Rural District of Pakistan
Conditions: Antepartum Hemorrhage; Postpartum Hemorrhage; Anemia; Eclampsia; Neonatal Sepsis; Birth Asphyxia; Diarrhoea; Pneumonia
Intervention: Maternal Neonatal And Child Health Interventions
Conditions: Antepartum Hemorrhage; Postpartum Hemorrhage; Anemia; Eclampsia; Neonatal Sepsis; Birth Asphyxia; Diarrhoea; Pneumonia
Intervention: Maternal Neonatal And Child Health Interventions
February 2, 2017
2721
NCT01832688
Completed
Completed
Assessment of the Nutritional Status of Pregnant Women and Optimization of Prenatal Care Services
Conditions: Pregnancy
Intervention: Programmatic Prenatal Care Optimization
Conditions: Pregnancy
Intervention: Programmatic Prenatal Care Optimization
July 17, 2018
2722
NCT01797055
Recruiting
Recruiting
Apotransferrin in Atransferrinemia
Conditions: Congenital Atransferrinemia
Intervention: Human Apotransferrin
Conditions: Congenital Atransferrinemia
Intervention: Human Apotransferrin
March 29, 2019
2723
NCT03572647
Completed
Completed
Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
Conditions: Renal Insufficiency, Chronic
Intervention: Eritromax, Eprex
Conditions: Renal Insufficiency, Chronic
Intervention: Eritromax, Eprex
June 19, 2018
2724
NCT00071032
Completed
Completed
Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease
Conditions: Anemia; Hematologic Diseases; Cardiovascular Diseases; Heart Diseases; Myocardial Infarction; Thromboembolism; Pneumonia; Cerebrovascular Accident
Intervention: Liberal (10 G/dL) Transfusion Strategy, Restrictive (Symptomatic) Transfusion Strategy
Conditions: Anemia; Hematologic Diseases; Cardiovascular Diseases; Heart Diseases; Myocardial Infarction; Thromboembolism; Pneumonia; Cerebrovascular Accident
Intervention: Liberal (10 G/dL) Transfusion Strategy, Restrictive (Symptomatic) Transfusion Strategy
August 14, 2014
2725
NCT01266421
Active, not recruiting
Active, not recruiting
Visanne Post-approval Observational Study (VIPOS)
Conditions: Endometriosis
Conditions: Endometriosis
August 9, 2018
2726
NCT03805776
Recruiting
Recruiting
Intermittent Fasting in Dyslipidemia
Conditions: Intermittent Fasting; Dyslipidemias; HDL Cholesterol, Low Serum; Hepatic Enzymes and Function Abnormalities; Anemia; Kidney Diseases; Cardiac Function
Intervention: Fasting (diet Restruction For Specific Period)
Conditions: Intermittent Fasting; Dyslipidemias; HDL Cholesterol, Low Serum; Hepatic Enzymes and Function Abnormalities; Anemia; Kidney Diseases; Cardiac Function
Intervention: Fasting (diet Restruction For Specific Period)
February 20, 2019
2727
NCT00005934
Completed
Completed
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
Conditions: Beta Thalassemia
Intervention: 5-Azacytidine
Conditions: Beta Thalassemia
Intervention: 5-Azacytidine
March 3, 2008
2728
NCT03876704
Recruiting
Recruiting
Effects of Fat-soluble Vitamins Supplementation on Common Complications and Neural Development in Very Low Birth Weight Infants
Conditions: Vitamin A Deficiency; Vitamin D Deficiency; Vitamin E Deficiency; Very Low Birth Weight Infants; Bronchopulmonary Dysplasia; Anemia; Sepsis
Intervention: High Dose Of Fat-Soluble Vitamin, Conventional Dose Of Fat-Soluble Vitamin
Conditions: Vitamin A Deficiency; Vitamin D Deficiency; Vitamin E Deficiency; Very Low Birth Weight Infants; Bronchopulmonary Dysplasia; Anemia; Sepsis
Intervention: High Dose Of Fat-Soluble Vitamin, Conventional Dose Of Fat-Soluble Vitamin
March 13, 2019
2729
NCT02950142
Active, not recruiting
Active, not recruiting
Evidence-based Laboratory Test Order Sets in Primary Care
Conditions: Diabetes Mellitus; Hypertension; Cardiovascular Diseases; Fatigue; Anemia; Liver Diseases; Medication Monitoring; Gout; Chronic Kidney Diseases; Lung Embolism; Acute Coronary Syndrome; Diarrhea; Thyroid Diseases; Sexually Transmitted Diseases; Rheumatoid Arthritis; Obesity; General Check-up
Intervention: CPOE With Order Sets For Lab Testing, CPOE Without Order Sets For Lab Testing
Conditions: Diabetes Mellitus; Hypertension; Cardiovascular Diseases; Fatigue; Anemia; Liver Diseases; Medication Monitoring; Gout; Chronic Kidney Diseases; Lung Embolism; Acute Coronary Syndrome; Diarrhea; Thyroid Diseases; Sexually Transmitted Diseases; Rheumatoid Arthritis; Obesity; General Check-up
Intervention: CPOE With Order Sets For Lab Testing, CPOE Without Order Sets For Lab Testing
October 10, 2018
2730
NCT03847753
Active, not recruiting
Active, not recruiting
Exploring the Comorbidity Between Mental Disorders and General Medical Conditions
Conditions: Organic, Including Symptomatic, Mental Disorders; Substance Use; Schizophrenia; Mood [Affective] Disorders; Neurotic, Stress-related and Somatoform Disorders; Eating Disorder; Disorders of Adult Personality and Behavior; Mental Retardation; Disorder of Psychological Development; Behavioural Disorder; Hypertension; Dyslipidemias; Ischemic Heart Disease; Atrial Fibrillation; Heart Failure; Peripheral Occlusive Disease; Stroke; Diabetes Mellitus; Thyroid Disorder; Gout; Chronic Pulmonary Disease; Allergy; Chronic Gastritis; Chronic Liver Disease; Inflammatory Bowel Diseases; Diverticular Disease of Large Intestine; Chronic Kidney Diseases; Prostate Disorders; Connective Tissue Disorder; Osteoporosis; Pain; HIV/AIDS; Anemia; Cancer; Vision Disorders; Hearing Disorders; Migraine; Epilepsy; Parkinson Disease; Multiple Sclerosis; Neuropathy
Intervention: Organic Disorders, Substance Use Disorders, Schizophrenia Disorders, Mood Disorders, Neurotic Disorders, Eating Disorders, Personality Disorders, Intellectual Disorders, Developmental Disorders, Behavioral Disorders
Conditions: Organic, Including Symptomatic, Mental Disorders; Substance Use; Schizophrenia; Mood [Affective] Disorders; Neurotic, Stress-related and Somatoform Disorders; Eating Disorder; Disorders of Adult Personality and Behavior; Mental Retardation; Disorder of Psychological Development; Behavioural Disorder; Hypertension; Dyslipidemias; Ischemic Heart Disease; Atrial Fibrillation; Heart Failure; Peripheral Occlusive Disease; Stroke; Diabetes Mellitus; Thyroid Disorder; Gout; Chronic Pulmonary Disease; Allergy; Chronic Gastritis; Chronic Liver Disease; Inflammatory Bowel Diseases; Diverticular Disease of Large Intestine; Chronic Kidney Diseases; Prostate Disorders; Connective Tissue Disorder; Osteoporosis; Pain; HIV/AIDS; Anemia; Cancer; Vision Disorders; Hearing Disorders; Migraine; Epilepsy; Parkinson Disease; Multiple Sclerosis; Neuropathy
Intervention: Organic Disorders, Substance Use Disorders, Schizophrenia Disorders, Mood Disorders, Neurotic Disorders, Eating Disorders, Personality Disorders, Intellectual Disorders, Developmental Disorders, Behavioral Disorders
August 27, 2019
2731
NCT03815175
Recruiting
Recruiting
XIENCE 28 USA Study
Conditions: Bleeding Disorder; Ischemic Stroke; Hemorrhagic Stroke; Hematological Diseases; Thrombocytopenia; Coagulation Disorder; Anemia; Renal Insufficiency; Coronary Artery Disease
Intervention: XIENCE, DAPT (aspirin And/or P2Y12 Receptor Inhibitor)
Conditions: Bleeding Disorder; Ischemic Stroke; Hemorrhagic Stroke; Hematological Diseases; Thrombocytopenia; Coagulation Disorder; Anemia; Renal Insufficiency; Coronary Artery Disease
Intervention: XIENCE, DAPT (aspirin And/or P2Y12 Receptor Inhibitor)
October 11, 2019
2732
NCT03814395
Recruiting
Recruiting
Peking University Birth Cohort in Tongzhou
Conditions: Health Problems in Pregnancy; Pregnancy Outcomes; Gestational Diabetes; Gestational Hypertension; Preterm Birth; Obesity; Mother-Infant Interaction; Child Development; Anemia
Intervention: No Intervention
Conditions: Health Problems in Pregnancy; Pregnancy Outcomes; Gestational Diabetes; Gestational Hypertension; Preterm Birth; Obesity; Mother-Infant Interaction; Child Development; Anemia
Intervention: No Intervention
January 24, 2019
2733
NCT03355742
Active, not recruiting
Active, not recruiting
XIENCE 28 Global Study
Conditions: Bleeding Disorder; Stroke, Ischemic; Stroke Hemorrhagic; Hematological Disease; Thrombocytopenia; Coagulation Disorder; Anemia; Renal Insufficiency; Coronary Artery Disease
Intervention: XIENCE, DAPT
Conditions: Bleeding Disorder; Stroke, Ischemic; Stroke Hemorrhagic; Hematological Disease; Thrombocytopenia; Coagulation Disorder; Anemia; Renal Insufficiency; Coronary Artery Disease
Intervention: XIENCE, DAPT
April 22, 2019
2734
NCT00278265
Terminated
Terminated
Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia
Conditions: T-Cell Large Granular Lymphocytic Leukemia
Intervention: MTX Followed By Fludarabine
Conditions: T-Cell Large Granular Lymphocytic Leukemia
Intervention: MTX Followed By Fludarabine
September 30, 2016
2735
NCT03073369
Withdrawn
Withdrawn
Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease
Conditions: CKD; Chronic Kidney Diseases; Hepcidin; Ergocalciferol; Vitamin D; Iron-deficiency; Anemia
Intervention: Ergocalciferol 50000 UNT, Placebo
Conditions: CKD; Chronic Kidney Diseases; Hepcidin; Ergocalciferol; Vitamin D; Iron-deficiency; Anemia
Intervention: Ergocalciferol 50000 UNT, Placebo
March 14, 2018
2736
NCT02860338
Completed
Completed
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
Conditions: Mild Cognitive Impairment; Dementia; Hypoxia; Hyperhomocysteinemia; Vitamin B 12 Deficiency; Iron Deficiency; Anemia; TBI; Neurodegenerative Disorders; Alzheimer's Disease; Vascular Dementia; Brain Injuries; Tauopathies; Parkinson's Disease; Lewy Body Dementia; Frontotemporal Dementia; TDP-43 Proteinopathies
Conditions: Mild Cognitive Impairment; Dementia; Hypoxia; Hyperhomocysteinemia; Vitamin B 12 Deficiency; Iron Deficiency; Anemia; TBI; Neurodegenerative Disorders; Alzheimer's Disease; Vascular Dementia; Brain Injuries; Tauopathies; Parkinson's Disease; Lewy Body Dementia; Frontotemporal Dementia; TDP-43 Proteinopathies
August 4, 2016
2737
NCT01135849
Completed
Completed
B-Receptor Signaling in Cardiomyopathy
Conditions: Carcinomas; Amyloidosis; Anal Cancer; Anemia; Cholangiocarcinoma of the Extrahepatic Bile Duct; Transitional Cell Carcinoma of Bladder; Bone Marrow Transplant Failure; Bone Cancer; Cancer of Brain and Nervous System; Breast Cancer; Carcinoma of the Large Intestine; Endocrine Cancer; Esophageal Cancer; Eye Cancer; Gall Bladder Cancer; Gastric (Stomach) Cancer; Gastrooesophageal Cancer; Gastrointestinal Stromal Tumor (GIST); Gynecologic Cancers; Head and Neck Cancers; Hepatobiliary Neoplasm; Kidney (Renal Cell) Cancer; Leukemia; Lung Cancer; Hodgkin Disease; Lymphoma, Non-Hodgkin; Mesothelioma; Multiple Myeloma; Myelodysplastic Syndromes (MDS); Neuroendocrine Tumors; Myeloproliferative Disorders; Pancreatic Cancer; Prostate Cancer; Skin Cancer; Soft Tissue Sarcoma; Testicular Cancer; Thymus Cancer; Thyroid Cancer
Conditions: Carcinomas; Amyloidosis; Anal Cancer; Anemia; Cholangiocarcinoma of the Extrahepatic Bile Duct; Transitional Cell Carcinoma of Bladder; Bone Marrow Transplant Failure; Bone Cancer; Cancer of Brain and Nervous System; Breast Cancer; Carcinoma of the Large Intestine; Endocrine Cancer; Esophageal Cancer; Eye Cancer; Gall Bladder Cancer; Gastric (Stomach) Cancer; Gastrooesophageal Cancer; Gastrointestinal Stromal Tumor (GIST); Gynecologic Cancers; Head and Neck Cancers; Hepatobiliary Neoplasm; Kidney (Renal Cell) Cancer; Leukemia; Lung Cancer; Hodgkin Disease; Lymphoma, Non-Hodgkin; Mesothelioma; Multiple Myeloma; Myelodysplastic Syndromes (MDS); Neuroendocrine Tumors; Myeloproliferative Disorders; Pancreatic Cancer; Prostate Cancer; Skin Cancer; Soft Tissue Sarcoma; Testicular Cancer; Thymus Cancer; Thyroid Cancer
November 16, 2015
2738
NCT00003123
Unknown status
Unknown status
Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome
Conditions: Myelodysplastic Syndromes
Intervention: Amifostine Trihydrate
Conditions: Myelodysplastic Syndromes
Intervention: Amifostine Trihydrate
November 5, 2013
2739
NCT00731328
Completed
Completed
Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Conditions: Leukemia; Myelodysplastic Syndromes; Nonmalignant Neoplasm; Paroxysmal Nocturnal Hemoglobinuria
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: Leukemia; Myelodysplastic Syndromes; Nonmalignant Neoplasm; Paroxysmal Nocturnal Hemoglobinuria
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
December 29, 2015
2740
NCT03895151
Active, not recruiting
Active, not recruiting
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children
Conditions: Nutritional Stunting; Nutritional Anemia; Nutritional Deficiency; Nutrigenetic; Nutrigenomic; Linear Programming; Food Based Recommendation
Intervention: Milk Supplementation, Food Based Recommendation (FBR) Nutrition Education
Conditions: Nutritional Stunting; Nutritional Anemia; Nutritional Deficiency; Nutrigenetic; Nutrigenomic; Linear Programming; Food Based Recommendation
Intervention: Milk Supplementation, Food Based Recommendation (FBR) Nutrition Education
May 9, 2019
2741
NCT04027309
Not yet recruiting
Not yet recruiting
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
Intervention: Gilteritinib, Midostaurin
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
Intervention: Gilteritinib, Midostaurin
August 6, 2019
2742
NCT03839771
Recruiting
Recruiting
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
Intervention: AG-120, Placebo For AG-120, AG-221, Placebo For AG-221
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
Intervention: AG-120, Placebo For AG-120, AG-221, Placebo For AG-221
July 16, 2019
2743
NCT03779854
Recruiting
Recruiting
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Conditions: Acute Biphenotypic Leukemia; Acute Leukemia; Acute Leukemia of Ambiguous Lineage; Acute Lymphoblastic Leukemia; Acute Undifferentiated Leukemia; Allogeneic Hematopoietic Stem Cell Transplantation Recipient; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blasts Under 25 Percent of Bone Marrow Nucleated Cells; Blasts Under 5 Percent of Bone Marrow Nucleated Cells; Mixed Phenotype Acute Leukemia; Myelodysplastic Syndrome With Excess Blasts-1; Myelodysplastic Syndrome With Excess Blasts-2
Intervention: Total-Body Irradiation, Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T Cell Replete BM), Tacrolimus, Methotrexate, Allogeneic Hematopoietic Stem Cell Transplantation (naive T Cell-depleted PBSC)
Conditions: Acute Biphenotypic Leukemia; Acute Leukemia; Acute Leukemia of Ambiguous Lineage; Acute Lymphoblastic Leukemia; Acute Undifferentiated Leukemia; Allogeneic Hematopoietic Stem Cell Transplantation Recipient; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blasts Under 25 Percent of Bone Marrow Nucleated Cells; Blasts Under 5 Percent of Bone Marrow Nucleated Cells; Mixed Phenotype Acute Leukemia; Myelodysplastic Syndrome With Excess Blasts-1; Myelodysplastic Syndrome With Excess Blasts-2
Intervention: Total-Body Irradiation, Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T Cell Replete BM), Tacrolimus, Methotrexate, Allogeneic Hematopoietic Stem Cell Transplantation (naive T Cell-depleted PBSC)
August 29, 2019
2744
NCT03670966
Recruiting
Recruiting
211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome
Conditions: Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia in Remission; CD45-Positive Neoplastic Cells Present; Chronic Myelomonocytic Leukemia; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts; Myeloproliferative Neoplasm; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia
Intervention: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Bone Marrow Transplantation, Tacrolimus, Mycophenolate Mofetil, Sirolimus, Granulocyte Colony-Stimulating Factor
Conditions: Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia in Remission; CD45-Positive Neoplastic Cells Present; Chronic Myelomonocytic Leukemia; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts; Myeloproliferative Neoplasm; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia
Intervention: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Bone Marrow Transplantation, Tacrolimus, Mycophenolate Mofetil, Sirolimus, Granulocyte Colony-Stimulating Factor
October 1, 2019
2745
NCT03383575
Recruiting
Recruiting
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia; Blasts 20-30 Percent of Bone Marrow Nucleated Cells; Chronic Myelomonocytic Leukemia; IDH2 Gene Mutation; Myelodysplastic Syndrome With Excess Blasts; Recurrent High Risk Myelodysplastic Syndrome; Refractory High Risk Myelodysplastic Syndrome
Intervention: Azacitidine, Enasidenib, Quality-of-Life Assessment
Conditions: Acute Myeloid Leukemia; Blasts 20-30 Percent of Bone Marrow Nucleated Cells; Chronic Myelomonocytic Leukemia; IDH2 Gene Mutation; Myelodysplastic Syndrome With Excess Blasts; Recurrent High Risk Myelodysplastic Syndrome; Refractory High Risk Myelodysplastic Syndrome
Intervention: Azacitidine, Enasidenib, Quality-of-Life Assessment
July 16, 2019
2746
NCT03338348
Recruiting
Recruiting
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
Intervention: Vosaroxin, Azacitidine
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
Intervention: Vosaroxin, Azacitidine
June 29, 2018
2747
NCT01039051
Unknown status
Unknown status
Diet and Lifestyle Intervention Study in Postpartum Women in China
Conditions: Puerperal Infection; Fever; Constipation; Hemorrhoids; Anal Fissure; Breast Disease; Oral Ulcers; Anemia
Intervention: Diet And Lifestyle Intervention In Chinese Postpartum Women
Conditions: Puerperal Infection; Fever; Constipation; Hemorrhoids; Anal Fissure; Breast Disease; Oral Ulcers; Anemia
Intervention: Diet And Lifestyle Intervention In Chinese Postpartum Women
December 23, 2009
2748
NCT03092674
Suspended
Suspended
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts-2
Intervention: Azacitidine, Cytarabine, Decitabine, Laboratory Biomarker Analysis, Midostaurin, Nivolumab
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts-2
Intervention: Azacitidine, Cytarabine, Decitabine, Laboratory Biomarker Analysis, Midostaurin, Nivolumab
October 14, 2019
2749
NCT03128034
Recruiting
Recruiting
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Conditions: Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia in Remission; High Risk Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome With Excess Blasts; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia; Recurrent Acute Lymphoblastic Leukemia; Recurrent Mixed Phenotype Acute Leukemia; Refractory Acute Myeloid Leukemia; Refractory Mixed Phenotype Acute Leukemia
Intervention: Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Pretargeted Radioimmunotherapy, Sirolimus, Total-Body Irradiation, Fludarabine
Conditions: Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia in Remission; High Risk Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome With Excess Blasts; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia; Recurrent Acute Lymphoblastic Leukemia; Recurrent Mixed Phenotype Acute Leukemia; Refractory Acute Myeloid Leukemia; Refractory Mixed Phenotype Acute Leukemia
Intervention: Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Pretargeted Radioimmunotherapy, Sirolimus, Total-Body Irradiation, Fludarabine
August 9, 2019
2750
NCT03096782
Active, not recruiting
Active, not recruiting
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Biphenotypic Leukemia; Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chemotherapy-Related Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Myelomonocytic Leukemia; Hodgkin Lymphoma; Langerhans Cell Histiocytosis; Minimal Residual Disease; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts; Non-Hodgkin Lymphoma; Recurrent Hodgkin Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Myelodysplastic Syndrome; Small Lymphocytic Lymphoma; Therapy-Related Myelodysplastic Syndrome
Intervention: Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Biphenotypic Leukemia; Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chemotherapy-Related Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Myelomonocytic Leukemia; Hodgkin Lymphoma; Langerhans Cell Histiocytosis; Minimal Residual Disease; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts; Non-Hodgkin Lymphoma; Recurrent Hodgkin Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Myelodysplastic Syndrome; Small Lymphocytic Lymphoma; Therapy-Related Myelodysplastic Syndrome
Intervention: Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
May 21, 2019
First Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 … 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 Next Last
Last Updated
The last updated date is the most recent date when changes to a clinical trial were
submitted to ClinicalTrials.gov. There is often a delay of a few days before the
updated trial is available on the clinical trials website.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
First Received
The first received date is the date when the clinical trial was first submitted
to ClinicalTrials.gov. There is often a delay of a few days before the
trial is available on the clinical trials website.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Safety Issue
If selected, restricts search results to those studies which have
an outcome measure designated as a safety issue. Note that this is a
poor estimate of the safety of a treatment or intervention, but it is
all we have now.
Funded By
Studies are supported by one or more organizations called sponsors.
Support includes contributions of facilities, expertise, and/or financial resources.
All sponsors in the database have been assigned one of the following organization types:
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
Study Phase
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Age Group
Studies may be designed for participants of particular ages:
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Gender
Searches can be restricted to studies which accept female or male participants.
Location Terms
If you are interested in a specific city (such as Los Angeles) or facility
name (such as the Mayo Clinic), enter it as a location term. Not all studies
include this level of detail, but if they do, this will find them.
Countries and States
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state.
Study IDs
Each trial is assigned one or more identification numbers by the institute, agency,
or organization sponsoring the trial. In addition, clinical trials assigns a
unique NCT identifier of the form NCTxxxxxxxx where each x is a numeric digit.
Use this box to search for a trial by NCT identifier or any other study
identification numbers.
Examples:
Examples:
NCT00001789
97-h-0197
ia0006
actg 076
97-h-0197
ia0006
actg 076
Sponsor (Lead)
Use this box to specify the name of an institute, organization, or company that is
conducting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Sponsor/Collaborators
Use this box to specify institutes, organizations, or companies that are
conducting or otherwise supporting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Outcome Measures
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Outcome measures are used to evaluate trial results. For example, an obesity treatment
might be evaluated by a measure of weight loss after 6 months. Measures can also be used
to quantify side effects, such as number of myocardial infarctions,
number of patients with heart arrhythmia, number of suicides, etc.
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Interventions
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Conditions
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Study Type
There are three types of studies available in ClinicalTrials.gov:
There are three types of studies available in ClinicalTrials.gov:
Interventional:
Observational:
Expanded Access:
Studies where individuals are assigned to receive specific interventions.
Participants may receive diagnostic, therapeutic or other types of interventions.
Assignment of the intervention may or may not be random.
Individuals are tracked and biomedical and/or health outcomes are assessed.
Observational:
Studies without an intervention.
Studies where biomedical and/or health outcomes are assessed in a pre-defined group of individuals.
Participants may receive diagnostic, therapeutic, or other interventions, but the investigator
does not assign specific interventions to the participants of the study.
Expanded Access:
Records describing the procedure for obtaining an experimental drug or device for patients who
are failing on currently available treatments for their condition and also are unable to
participate in ongoing clinical trials. Expanded Access records are used to register all
types of non-protocol access to experimental treatments, including protocol exception,
single-patient IND, treatment IND, compassionate use, emergency use, continued access and parallel track.
Study Results
Searches can be restricted to studies with or without results.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
Recruitment Status
Also known as Enrollment Status.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Search Terms
Use this box to specify general search terms found anywhere in the trial record.
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Help for Searching clinical trials
Help Topics:
Basic Search:
On the Basic Search page, enter a word or word(s) that you want to use to find studies.
These may include diseases, interventions, and/or locations.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
Use of a Pacemaker Following a Heart Attack.
higher than the study,
Heart Defects and Transient Ischemic Attacks
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Advanced Search:
Many searches are a single term and can be performed with a few words in the
search box. But, sometimes you need more control. Click on the Advanced Search tab
(if starting a new search) or Refine Search tab (if modifying an existing search)
to show additional search fields.
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Recruitment:
Interventions:
Outcomes Measures:
Sponsor/Collaborators:
Sponsor (Lead):
Study IDs:
Country/State:
Location Terms:
Gender:
Age Group:
Phase:
Funded By:
Safety Issue:
First Received:
Last Updated:
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Performs a general search in all sections of the study record, including title,
description, conditions, interventions, locations, etc. Terms in this field are
searched the same as Basic Search.
Recruitment:
Limits search results to studies that are open or closed. New volunteers may be
able to participate in open studies, but not closed studies.
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Study Results:Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Values are color coded (as shown) in the search results.
Limits search results based on whether the study has results or not:
Study Type:
All Studies,
Studies With Results, or
Studies Without Results
The inclusion of Study Results is a new feature of ClinicalTrials.gov.
Only a few studies have results available.Studies With Results, or
Studies Without Results
Limits search results to any of the following study types:
Conditions:
Interventional,
Observational, or
Expanded Access
Observational, or
Expanded Access
Performs a search on fields describing the diseases or conditions being studied.
Interventions:
Performs a search on fields listing the drugs or interventions being studied.
Outcomes Measures:
Performs a search on fields listing the outcome measures used to quantify study results.
Sponsor/Collaborators:
Performs a search on fields listing the sponsor and collaborators of a study.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Sponsor (Lead):
Performs a search on the sponsor field of a study.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Study IDs:
Performs a search on fields listing ID numbers.
Country/State:
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state (e.g., United States, Alabama).
Location Terms:
Finds studies in specific locations such as a city (Los Angeles) or facility (Mayo Clinic).
Not all studies include this level of detail, but if they do, this will find them.
Gender:
Limits search results to those studies that accept female or male participants.
Age Group:
Limits search results to those studies that include at least one of the specified age
ranges. More than one age group can be selected.
Phase:
Limits search results to studies that are labeled with at least one of the specified
phases. More than one Phase can be selected.
Funded By:
Limits search results to studies that have at least one sponsor of the specified types.
More than one sponsor type can be selected.
Safety Issue:
Limits search results to studies that have at least one outcome measure designated as a safety issue.
First Received:
Limits search results to studies that were received by clinical trials within a
specified date range. The "From" or "To" field can be left blank.
Last Updated:
Limits search results to studies that were modified within a
specified date range. The "From" or "To" field can be left blank.
Refine Search:
Searches display a list of studies found (List Results tab). If you are not content with
the search results, click on the Refine Search tab at the top of the list to modify your
search.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
When you are done making changes, click Search to display the new results.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
heart attack
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
When you are done making changes, click Search to display the new results.
Search Expressions:
Use AND (all upper case) to find study records that contain all terms connected by AND.
For example:
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.
For example:
prostate cancer AND radiation
heart disease AND stroke AND California
heart disease AND stroke AND California
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Aspirin OR ibuprofen
heart disease OR heart attack
heart disease OR heart attack
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Immunodeficiency NOT AIDS
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
prostate cancer AND NOT ( radiation OR homeopathic remedies )
( heart disease OR heart attack ) AND ( stroke OR clot )
( heart disease OR heart attack ) AND ( stroke OR clot )
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
Ear, Nose, and Throat Conditions
is the expression
( Ear OR Nose OR Throat ) AND Conditions
Fortunately, search will do a pretty good job of finding the right studies either way.To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.